Clinical Trials Logo

Cerebral Infarction clinical trials

View clinical trials related to Cerebral Infarction.

Filter by:

NCT ID: NCT06140888 Not yet recruiting - Clinical trials for Acute Ischemic Stroke

Effect of Ginkgo Biloba Extract on Cognitive Function in Acute Ischemic Stroke

Start date: March 15, 2024
Phase: N/A
Study type: Interventional

The purpose of this study is to determine the effect of ginkgo biloba extract on cognitive function in acute ischemic stroke.

NCT ID: NCT06139692 Recruiting - Clinical trials for Acute Ischemic Stroke

Comparison of Perioperative Conscious Sedation During Endovascular Thrombectomy in Acute Ischemic Stroke

PEACE
Start date: November 21, 2023
Phase: Phase 4
Study type: Interventional

This study aims to conduct a multicenter, prospective, randomized clinical trial to scientifically evaluate the safety and efficacy of different perioperative sedation methods during endovascular thrombectomy in acute ischemic stroke patients with large vessel occlusion in the anterior circulation.

NCT ID: NCT06138834 Not yet recruiting - Clinical trials for Acute Ischemic Stroke

EFfects of Y-6 SUblingual Tablets foR PaTients With AcUte Ischemic StRokE (FUTURE)

Start date: November 2023
Phase: Phase 2
Study type: Interventional

This study aims to evaluate the efficacy of Y-6 sublingual tablets in improving microcirculation dysfunction and reducing thrombo-inflammation in patients who had AIS caused by LVO and received reperfusion therapy. Moreover, we expect to evaluate the safety of using Y-6 sublingual tablet in such study population.

NCT ID: NCT06138210 Recruiting - Clinical trials for Acute Ischemic Stroke

The Effect of GD-iExo-003 in Acute Ischemic Stroke

ExoCURE
Start date: May 27, 2024
Phase: Phase 1
Study type: Interventional

This is a multicenter, randomized, double-blinded, placebo-controlled, dose-escalation trial. The objective of this study is evaluating safety and preliminary efficacy of intravenous exosomes derived from human induced pluripotent stem cell (GD-iExo-003) in acute ischemic stroke.

NCT ID: NCT06137300 Not yet recruiting - Clinical trials for Acute Ischemic Stroke

Safety and Efficacy of Urinary Kallidinogenase for Large Artery Atherosclerosis Acute Ischemic Stroke

Start date: March 15, 2024
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate the safety and efficacy of urinary kallidinogenase treatment in patients with large artery atherosclerotic acute ischemic stroke.

NCT ID: NCT06135103 Recruiting - Ischemic Stroke Clinical Trials

Phase 2 Study of TXA127 in Post-ischemic Stroke Patients

Start date: November 26, 2023
Phase: Phase 2
Study type: Interventional

This is a 50-patient, Phase 2, double-blind, randomized, placebo-controlled, hybrid decentralized study to evaluate the safety and efficacy of daily subcutaneous (SC) injection of TXA127 in post-ischemic stroke patients. Subjects will receive either TXA127 0.5mg/kg or placebo for 12 weeks started 6 to 24 months post ischemic stroke, and they will have a 12 week follow up visit after treatment has ended. The primary efficacy outcome measure is individual patient absolute change from baseline in motor and sensory functions as measured by the Fugl-Meyer Assessment of Upper Extremity (FMA-UE) 12 weeks after start of treatment.

NCT ID: NCT06134635 Not yet recruiting - Clinical trials for Acute Ischemic Stroke

Short-term Effect of PCSK9 Inhibitor in Patients With Acute Ischemic Stroke

Start date: December 1, 2023
Phase:
Study type: Observational

This is a prospective cohort study to investigate the early impact of evolocumab on patients with acute ischemic stroke (AIS) in China. Evolocumab, a proprotein convertase subtilisin/kexin taye 9 inhibitor, can significantly reduce low density lipoprotein cholesterol (LDL-C) levels and has a positive effect on improving cardiovascular events. However, existing studies have focused almost exclusively on the long-term effects of Evolocumab, and the early effects of Evolocumab on AIS patients remains unclear.

NCT ID: NCT06132880 Not yet recruiting - Clinical trials for Acute Ischemic Stroke

Effects of Human Urinary Kallidinogenase on Early Improvement and Functional Outcomes in Acute Ischemic Stroke (TK-SPEED)

Start date: December 14, 2023
Phase: N/A
Study type: Interventional

The primary purpose of this trial is to evaluate the effects of Human Urinary Kallidinogenase on improvement of neurological outcome, and early cerebral perfusion in acute ischemic stroke.

NCT ID: NCT06129175 Recruiting - Clinical trials for Acute Ischemic Stroke

UCMSCs as Treatment for Patients With Acute Ischemic Stroke (Stroke Neuroncell-EX)

Start date: December 19, 2023
Phase: Phase 2/Phase 3
Study type: Interventional

The primary objective of this study is to evaluate the functional recovery based on Barthel index (BI) and modified Rankin Scale (mRS) while the secondary objectives are to assess the survival and re-admission rate as well as to investigate the inflammatory response in a subclinical study within 1 year of Neuroncell-EX infusion in participants with acute ischemic stroke.

NCT ID: NCT06125236 Recruiting - Clinical trials for Acute Ischemic Stroke

Registration of Acute Ischemic Stroke With Large and Medium-sized Vascular Occlusion in Southwest China(LMVOS)

LMVOS
Start date: November 9, 2023
Phase:
Study type: Observational

This study is designed to observe the treatment options in real-world clinical practice as well as the safety and efficacy of different treatment strategies.